3-38477333-C-T
Variant names: 
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_ModerateBP6_ModerateBP7BS2
The NM_001106.4(ACVR2B):c.99C>T(p.Asn33Asn) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000483 in 1,614,166 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★).
Frequency
 Genomes: 𝑓 0.000039   (  0   hom.,  cov: 32) 
 Exomes 𝑓:  0.000049   (  0   hom.  ) 
Consequence
 ACVR2B
NM_001106.4 synonymous
NM_001106.4 synonymous
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  0.297  
Publications
1 publications found 
Genes affected
 ACVR2B  (HGNC:174):  (activin A receptor type 2B) Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008] 
ACVR2B Gene-Disease associations (from GenCC):
- heterotaxy, visceral, 4, autosomalInheritance: AD Classification: STRONG, LIMITED Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -9 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.29). 
BP6
Variant 3-38477333-C-T is Benign according to our data. Variant chr3-38477333-C-T is described in ClinVar as Likely_benign. ClinVar VariationId is 471681.Status of the report is criteria_provided_single_submitter, 1 stars. 
BP7
Synonymous conserved (PhyloP=0.297 with no splicing effect.
BS2
High AC in GnomAd4 at 6 AD gene. 
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|---|---|---|---|---|---|---|---|---|---|
| ACVR2B | ENST00000352511.5 | c.99C>T | p.Asn33Asn | synonymous_variant | Exon 2 of 11 | 1 | NM_001106.4 | ENSP00000340361.3 | ||
| ACVR2B | ENST00000461232.1 | n.3888C>T | non_coding_transcript_exon_variant | Exon 1 of 10 | 1 | |||||
| ACVR2B | ENST00000465020.5 | n.103C>T | non_coding_transcript_exon_variant | Exon 2 of 10 | 2 | 
Frequencies
GnomAD3 genomes  0.0000394  AC: 6AN: 152188Hom.:  0  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
6
AN: 
152188
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.0000836  AC: 21AN: 251246 AF XY:  0.000103   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
21
AN: 
251246
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.0000493  AC: 72AN: 1461860Hom.:  0  Cov.: 31 AF XY:  0.0000756  AC XY: 55AN XY: 727232 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
72
AN: 
1461860
Hom.: 
Cov.: 
31
 AF XY: 
AC XY: 
55
AN XY: 
727232
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
33478
American (AMR) 
 AF: 
AC: 
0
AN: 
44724
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
26134
East Asian (EAS) 
 AF: 
AC: 
1
AN: 
39700
South Asian (SAS) 
 AF: 
AC: 
51
AN: 
86258
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
53416
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
5766
European-Non Finnish (NFE) 
 AF: 
AC: 
18
AN: 
1111988
Other (OTH) 
 AF: 
AC: 
2
AN: 
60396
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.471 
Heterozygous variant carriers
 0 
 9 
 17 
 26 
 34 
 43 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome  0.0000394  AC: 6AN: 152306Hom.:  0  Cov.: 32 AF XY:  0.0000537  AC XY: 4AN XY: 74480 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
6
AN: 
152306
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
4
AN XY: 
74480
show subpopulations 
African (AFR) 
 AF: 
AC: 
1
AN: 
41570
American (AMR) 
 AF: 
AC: 
0
AN: 
15302
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
3468
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
5176
South Asian (SAS) 
 AF: 
AC: 
4
AN: 
4830
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
10626
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
1
AN: 
68014
Other (OTH) 
 AF: 
AC: 
0
AN: 
2114
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.483 
Heterozygous variant carriers
 0 
 1 
 1 
 2 
 2 
 3 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
ClinVar
Significance: Likely benign 
Submissions summary: Benign:1 
Revision: criteria provided, single submitter
LINK: link 
Submissions by phenotype
Heterotaxy, visceral, 4, autosomal    Benign:1 
Feb 15, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
 RBP_binding_hub_radar 
 RBP_regulation_power_radar 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.